생물학적 안전성 시험 제품 및 서비스 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 시험 유형별, 지역별, 부문 예측(2025-2033년)

Biological Safety Testing Products And Services Market Size, Share & Trends Analysis Report By Product, By Application, By Test Type, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

생물학적 안전성 시험 제품 및 서비스 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 생물학적 안전성 시험 제품 및 서비스 시장 규모는 2033년까지 120억 9,000만 달러에 이르며, 2025년부터 2033년까지의 CAGR은 10.64%를 나타낼 것으로 예측됩니다.

이 시장은 생물학적 제제의 생산이 증가하고 매우 효과적인 생물학적 안전성 시험 도구 수요가 높아지고 있는 것이 주요 요인입니다.

당뇨병과 암 등 라이프스타일과 관련된 만성질환의 유병률 증가는 의약품 개발과 그에 따른 상업화 증가에 기여하는 주요 요인입니다. 오염이 없는 고활성의 생물 제제를 제조하는 생물학적 안전성 시험 제품 및 서비스를 점점 통합하게 되고 있습니다. 바이러스성 질환에 대한 안전성 시험은 생물 제제의 제조, 화학, 관리의 중요한 요소이기 때문에 많은 기업에 있어 주요한 관심사의 하나가 되고 있습니다.

실험실 기반 오염은 생물학적 안전성 시험 제품 및 서비스를 통합한 워크스테이션의 개발과 개선으로 이어졌습니다. 이에 따라 제품의 무결성에 대한 우려가 높아지고 있습니다. 적정 제조 기준(GMP)의 실시와 이어지는 각 생산 단계에서의 시험·관리에 대한 정부 의료기관의 관여 증가는 성장의 폭을 넓힐 것으로 예측됩니다.

게다가 생물학적 안전성 시험 제품 및 서비스 시장에서 사업을 전개하는 주요 기업은 생물학적 안전성 시험에 대한 세계 수요 증가에 대응하기 위해 신제품과 신기술의 개발, 제품 포트폴리오의 추가 확충에 끊임없이 주력하고 있습니다. 2022년 12월 Charles River Laboratories International, Inc.는 물, 공정 중 및 최종 제품 테스트를 위한 복잡한 또는 희석되지 않은 연속 희석액을 모두 처리할 수 있는 완전 로봇 기기인 Endosafe Nexus 200을 출시하여 내독소 테스트 포트폴리오를 더욱 확장한다고 발표했습니다.

생물학적 안전성 시험 제품 및 서비스 시장 보고서 하이라이트

• 제품별로는 시약 및 키트 분야가 연구·임상실험에서의 광범위한 사용으로 2024년에는 39.69% 이상의 주요 수익 점유율을 차지했습니다.
• 용도별로는 백신·치료제 분야가 2024년 시장 점유율로 우위를 차지했고, 오랜 기간에 걸친 질병 발생 증가에 의해 가장 빠른 성장률이 예상됩니다.
• 검사 유형별로는 세균 감염증 증가에 의해 엔도톡신 검사 분야가 2024년 시장 점유율로 우위를 차지했습니다.
• 북미는 바이오테크놀러지에 대한 연구 투자 증가와 만성질환 부담 증가로 2024년 수익 점유율 36.59%로 시장 전체를 지배했습니다.
• 아시아태평양은 인도나 중국과 같은 개발도상국에서의 헬스케어 지출 증가와 헬스케어 인프라의 개발에 의해 예측기간 중에 가장 빠른 성장률로 성장할 것으로 예측되고 있습니다.

목차

제1장 생물학적 안전성 시험 제품 및 서비스 시장 : 조사 방법과 범위

제2장 생물학적 안전성 시험 제품 및 서비스 시장 : 주요 요약

• 시장 현황
• 제품 및 용도의 스냅샷
• 테스트 유형의 스냅샷
• 경쟁 구도의 스냅샷

제3장 생물학적 안전성 시험 제품 및 서비스 시장 변수, 동향, 범위

• 시장 세분화 및 범위
• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조시장 전망
• 시장 역학
• 시장 성장 촉진요인 분석
  • 정부의 대처나 권고 증가
  • 질병 부담 증가에 의한 신규 생물 제제의 생산 증가
  • 임상조사와 생명과학 연구에 대한 많은 연구개발 투자
• 시장 성장 억제요인 분석
  • 시간이 걸리는 승인 프로세스
• Porter's Five Forces 분석
• PESTLE 분석
• 파이프라인 분석

제4장 생물학적 안전성 시험 제품 및 서비스 시장 : 제품 추정·동향 분석

• 생물학적 안전성 시험 제품 및 서비스 시장 : 제품 변동 분석
• 시약 및 키트
• 서비스
• 기기

제5장 생물학적 안전성 시험 제품 및 서비스 시장 : 용도 추정·동향 분석

• 생물학적 안전성 시험 제품 및 서비스 시장 : 용도 변동 분석
• 백신 및 치료제
  • 백신
  • 단일클론항체
  • 재조합 단백질
• 혈액 및 혈액 유래 제품
• 유전자 치료
• 조직 및 조직 기반 제품
• 줄기세포

제6장 생물학적 안전성 시험 제품 및 서비스 시장 : 시험 유형 추정·동향 분석

• 생물학적 안전성 시험 제품 및 서비스 시장 : 시험 유형 변동 분석
• 내독소 검사
• 무균 시험
• 세포주 인증 및 특성화 시험
• 생체 부담 시험
• 외래 물질 검출 시험
• 잔류 호스트 오염 탐지 시험
• 기타

제7장 생물학적 안전성 시험 제품 및 서비스 시장 : 지역 비즈니스 분석

• 지역 시장 현황
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 기업 분류
• 전략 매핑
  • 신제품 발매
  • 파트너십
  • 취득
  • 콜라보레이션
  • 자금조달
• 주요 기업의 시장 점유율 분석(2022년)
• 기업 히트맵 분석
• 기업 프로파일
  • Charles River Laboratories
  • BSL Bioservice
  • Lonza
  • Merck KGaA(MilliporeSigma)
  • Samsung Biologics
  • Sartorius AG
  • Eurofins Scientific
  • SGS Societe Generale de Surveillance SA
  • Thermo Fisher Scientific Inc.
  • BIOMERIEUX

KTH

영문 목차

영문목차

Biological Safety Testing Products And Services Market Growth & Trends:

The global biological safety testing products and services market size is expected to reach USD 12.09 billion by 2033, registering a CAGR of 10.64% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is predominantly driven by the increasing production of biologics, boosting the demand for highly effective biological safety testing tools. The increasing disease burden is expected to be a major factor responsible for the rising production of biologics, thereby propelling the market growth.

The increasing prevalence of chronic diseases associated with lifestyle, including diabetes and cancer, is a key factor contributing to the rise in drug development and subsequent commercialization. This is expected to increase the need for ensuring & scrutinizing the safety of specialized and targeted therapies, evaluating outcomes, and circumventing probable shortcomings. In addition, biotechnology and pharmaceutical companies are increasingly integrating biological safety testing products and services to produce contamination-free and highly potent biologics to cater to the large number of people suffering from target diseases. Safety testing for viral conditions is proving to be one of the primary concerns of most companies as it is a critical component of manufacturing, chemistry, and control of biologics. This is fueling growth opportunities in the market.

Laboratory-based contamination is leading to the development and refinement of workstations by incorporating biological safety products and services. The increasing need to work with tissue cultures, maintain the sterility of cell lines, and minimize cross-contamination has increased concerns regarding product integrity. Rising involvement by government healthcare organizations for implementing good manufacturing practices and subsequent testing & control at every production stage is expected to widen the scope for growth.

Furthermore, key players operating in the biological safety testing product & services market are constantly focusing on developing novel products and technologies, further expanding their product portfolio, and to meet the rising demand for biological safety testing globally. For instance, in December 2022, -Charles River Laboratories International, Inc. announced the launch of Endosafe Nexus 200, a fully robotic instrument capable of processing both complex or undiluted, serial dilutions for water, in-process, and final product testing, further expanding its endotoxin testing portfolio. The incorporation of automation through robotics has enabled streamlining the quality control process and subsequently improving overall process efficiency.

Biological Safety Testing Products And Services Market Report Highlights:

• Based on product, the reagents and kits segment held a leading revenue share of over 39.69% in 2024, due to their extensive use in research and clinical laboratories
• Based on application, the vaccines & therapeutics segment dominated in terms of market share in 2024 and is anticipated to grow at fastest growth rate owing to the increase in disease outbreaks over the years
• Based on test type, the endotoxin tests segment dominated in terms of the market share of in 2024, owing to the rising prevalence of bacterial infections
• North America dominated the overall market with a revenue share of 36.59% in 2024, owing to rising research investments in biotechnology and the growing burden of chronic diseases. This anticipates increasing the demand for molecular cytogenetics in the region over the forecast period
• Asia Pacific is anticipated to grow at the fastest growth rate over the forecast period due to growing healthcare spending and the development of healthcare infrastructure in developing countries like India and China

Table of Contents

Chapter 1. Biological Safety Testing Products & Services Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. Test Type segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Biological Safety Testing Products & Services Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product and Application Snapshot
• 2.3. Test Type Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Biological Safety Testing Products & Services Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Increasing number of government initiatives and recommendations
  • 3.4.2. Increasing production of new biologics due to high disease burden
  • 3.4.3. High R&D investments in clinical research and life sciences research
• 3.5. Market Restraint Analysis
  • 3.5.1. Time-consuming approval process
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Biological Safety Testing Products & Services Market: Product Estimates & Trend Analysis

• 4.1. Biological Safety Testing Products & Services Market: Product Movement Analysis
• 4.2. Reagents & Kits
  • 4.2.1. Reagents & Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Services
  • 4.3.1. Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Biological Safety Testing Products & Services Market: Application Estimates & Trend Analysis

• 5.1. Biological Safety Testing Products & Services Market: Application Movement Analysis
• 5.2. Vaccines & Therapeutics
  • 5.2.1. Vaccines & Therapeutics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.2. Vaccines
    • 5.2.2.1. Vaccines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.3. Monoclonal Antibodies
    • 5.2.3.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.4. Recombinant Protein
    • 5.2.4.1. Recombinant Protein Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Blood & Blood-based Products
  • 5.3.1. Blood & Blood-based Products Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Gene Therapy
  • 5.4.1. Gene Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Tissue & Tissue-based Products
  • 5.5.1. Tissue & Tissue-based Products Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Stem Cells
  • 5.6.1. Stem Cells Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Biological Safety Testing Products & Services Market: Test Type Estimates & Trend Analysis

• 6.1. Biological Safety Testing Products & Services Market: Test Type Movement Analysis
• 6.2. Endotoxin Tests
  • 6.2.1. Endotoxin Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Sterility Tests
  • 6.3.1. Sterility Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Cell Line Authentication & Characterization Tests
  • 6.4.1. Cell Line Authentication & Characterization Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Bioburden Tests
  • 6.5.1. Bioburden Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Adventitious Agent Detection Tests
  • 6.6.1. Adventitious Agent Detection Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Residual Host Contamination Detection Tests
  • 6.7.1. Residual Host Contamination Detection Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Biological Safety Testing Products & Services Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Biological Safety Testing Products & Services Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germnay
    • 7.3.3.1. Germany Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. MEA
  • 7.6.1. MEA Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Biological Safety Testing Products & Services Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Product Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboaration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2022
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. Charles River Laboratories
    • 8.5.1.1. Company Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. BSL Bioservice
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Lonza
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Merck KGaA (MilliporeSigma)
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Samsung Biologics
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Sartorius AG
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Eurofins Scientific
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. SGS Societe Generale de Surveillance SA
    • 8.5.8.1. Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Thermo Fisher Scientific Inc.
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. BIOMERIEUX
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

관련자료